Research on the different mechanisms for crossing HLA barriers has progressed over the past 10 years. General outlines have come into view for a solution to this issue and are often presented as 'haploidentical SCT' immunology. In this review, we discuss several mechanisms that have recently been described in ex vivo and in vivo settings that can either avoid GVHD or promote hematopoietic reconstitution in haploidentical settings. The host and donor T-cell responses to allogeneic HLA molecules are a fundamental obstacle to the successful application of haploidentical transplantation, which results in unacceptably high incidences of GVHD and graft rejection. Thus, the T-cell response is a central factor in the establishment of a novel haploidentical transplant protocol with superior outcomes.
INTRODUCTION
Haploidentical SCT is an alternative transplant option for the majority of patients with hematological disease and is available without search or acquisition costs to the patient. [1] [2] [3] [4] [5] [6] [7] However, the success of haploidentical SCT is hindered by the host and donor T-cell response to allogeneic HLA molecules resulting in unacceptably high incidences of GVHD and graft rejection. The questions of how allografts can avoid rejection from a haploidentical recipient immune system and how normal host tissues can avoid attack by donor alloreactive immune cells have intrigued immunologists and hematologists alike for nearly 30 years. 5, [8] [9] [10] [11] [12] [13] [14] A great deal of work had been conducted to devise strategies to overcome this immunological barrier. These include ex-vivo graft T-cell depletion (TCD) 8, 15, 16 and CD3/CD19 depletion, 17 immune tolerance induced by G-CSF, 1, 4, [18] [19] [20] [21] [22] [23] and post transplantation CY for tolerance induction. 21, 24 In this review, we summarize the recent advances in haploidentical SCT and focus on the mechanisms underlying the strategies that can be used to overcome the HLA barrier. We indicate which mechanisms are most likely to have the greatest impact on the future establishment of better transplant protocols with superior clinical outcomes.
MECHANISMS RELEVANT TO HAPLOIDENTICAL SCT
Several mechanisms, 13, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] such as clonal deletion and anergy, veto effects, [35] [36] [37] [38] [39] Th2 polarization, regulatory T-cell (CD4 þ CD25 þ Foxp3 þ T cells, Tregs)-mediated suppression [40] [41] [42] and natural killer (NK) cell alloreactivity, 14, 43, 44 have been implicated in inducing immune tolerance ( Table 1 ). The mechanisms relevant to haploidentical SCT include: (1) alloreactive TCD and/or B-cell depletion as well as T-cell anergy; (2) veto activity of 'mega-dose CD34 þ cells', 12 which can suppress CTL precursor cells directed against their own Ags, but not those directed against third-party Ags; 45 (3) polarization of T cells from Th1 to Th2 phenotype, the Th2 cells can ameliorate severe GVHD via IL-4 and IL-10 production and potentially via IL-2 consumption and APC modulation. 29, 30, 46 In addition, Tregs can ameliorate acute GVHD by modulating IL-10 and TGF-b secretion and polarizing the Treg/Th17 balance toward Treg. 47 (4) In a mouse model of haploidentical transplant, Ruggeri et al.
14 showed that alloreactive NK cells ablated AML cells, killed recipient T cells and ablated the recipient dendritic cells (DCs). These NK cell functions, respectively, improved engraftment, protected from GVHD and reduced relapse in patients with AML. Currently, donor NK cell alloreactivity is established as a key element in haploidentical transplant. 5, 16, 43 More recently, several mechanistic insights into pertinent haploidentical SCT strategies have been reported. In a murine model, anti-third-party CD8 T cells actively respond to host attack by secreting polarizing cytotoxic granules when recognized by the TCR of host T cells, the main effector cells contributing to graft rejection. This perforin-dependent veto activity eliminates host T cells through the activation of the Fas-FasL pathway without causing GVHD. 13, 48, 49 In brief, anti-third-party CD8 T cells may represent an attractive and effective modality for the induction of transplantation tolerance across major genetic barriers. 5, 6 STRATEGIES USED TO OVERCOME HLA BARRIERS Several strategies, such as ex vivo TCD, treatment of healthy donors with G-CSF, post transplant CY (PT/CY) and pharmacological agents, such as ATG and CsA, have been implicated in crossing HLA barriers (Table 1) . [35] [36] [37] [38] EX VIVO TCD The Perugia group pioneered an approach for graft TCD via the positive selection of CD34 þ stem cells. However, NK cells, monocytes and DCs that contribute to immune reconstitution after transplantation were simultaneously depleted in this approach. 5, 16 Researchers from Germany performed a different TCD method in which CD3
þ /CD19 þ cells were depleted, but NK cells, monocytes and DCs were retained. 17 More recently, Locatelli et al. 50 developed another TCD method based on the physical elimination of mature T cells carrying the a and b chains of the TCR. This maintains the presence of mature donor-derived alloreactive NK cells and gd þ T cells in the graft. Overall, the goal of these strategies is to deplete alloreactive T and/or B cells in the allograft to avoid GR and GVHD development after haploidentical transplantation. 5, 16, 17, 50 TREATMENT OF HEALTHY DONORS WITH G-CSF Nearly one decade ago, G-CSF was recognized as a novel mediator of T-cell tolerance. 19, 22, [51] [52] [53] [54] Franzke et al. 19 demonstrated that G-CSF upregulated GATA-3 expression in human CD4 þ T cells and polarized CD4
þ T-cell differentiation toward a Th2 type. Th2 differentiation was associated with an increase in IL-4 and a decrease in IFN-g production as well as the suppression of ISGF3-g subunit/p48 gene expression in CD4 þ T cells. However, the immune modulatory effect of G-CSF on T cells is believed to be mediated exclusively through other effector cells. 18 For example, G-CSF treatment mobilized monocytes with the downregulated expression of costimulatory molecules, increased IL-10 production 55 and decreased secretion of IL-12 and TNF-a. 56 G-CSF also resulted in the selective mobilization of type 2 DCs, which promote T-cell differentiation toward the Th2 phenotype. 52 Similarly, naïve CD4 þ T cells activated in vitro with regulatory or tolerogenic DCs that were generated by treating donors with G-CSF were hyporesponsive and acquired an IL-10
þ cytokine secretion profile. 53 Impressively, G-CSF-mobilized donor cells contained the characteristic phenotype of mononuclear and polymorphonuclear myeloidderived suppressor cell-subtypes, 20, 57 as well as regulatory B cells (CD19 þ CD24 high CD38 high ) 18 that have the capacity to regulate alloreactive T-cell responses. In addition to G-CSF mediating the induction of immune tolerance by anergic mechanisms 54 and Th2 polarization, 51, 52 9, [58] [59] [60] it is reasonable to presume that patients who undergo haploidentical transplantation using plerixaforstimulated allografts may experience a lower incidence of GVHD. Moreover, plerixafor-mobilized stem cell grafts have been shown to successfully induce early engraftment across the MHCmediated haploidentical barrier in canines. 61 G-CSF plus plerixafor-mobilized grafts from patients with malignant disease contained a significantly higher number of plasmacytoid DCs than did those of G-CSF alone. These plasmacytoid DCs had potential regulatory capacity. 62 If these effects are confirmed in healthy donors, plerixafor may represent a new strategy for crossing HLA barriers. [60] [61] [62] PT/CY In vivo CY treatment may establish bi-directional tolerance through a number of mechanisms. Luznik et al. 21, 24 described three key steps in CY-induced tolerance. The first step includes destruction of peripheral, alloantigen-reactive T cells. Several lines of evidence support the differential sensitivity of naïve T cells versus effector (Teff)/memory T cells to CY-mediated killing. Therefore, a relative resistance of donor Teff/memory T cells to PT/CY, as demonstrated in mice, may contribute to the overall reconstitution of peripheral T-cell pools and immune competence in the long term. 24 These processes are important given the slow recovery of thymic and T-cell functions after transplantation.
The second step in CY-induced tolerance is the intrathymic clonal deletion of graft-reactive T cells. The existence of intrathymic clonal deletion after PT/CY was confirmed by using superantigen-disparate murine allo-combinations, 63 a well-studied system to explain self-tolerance. In addition to T cells that are initially transferred during the graft, T cells that emerge from the thymus contribute to the peripheral T-cell pool. These cells may shape clinical outcomes after transplantation by affecting the overall Treg/Teff balance. 24 In the final key step of CY tolerance, there is a late breakdown of clonal deletion and an emergence of regulatory, or 'suppressor', T cells. 10, 21 The notion that CD4 þ Tregs may also contribute to CY-induced tolerance is consistent with recent observations that Foxp3 þ Tregs are critical for tolerance induction in MHC-matched and -mismatched models that use anti-T-cell Abs and a co-stimulatory blockade. The numbers showed in the parentheses following each strategy represent the corresponding mechanism of immune tolerance.
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Luzinik et al. 21 also proposed a three-phase hypothesis for tolerance induction by CY, which includes three distinct phases: induction, transition and maintenance. The 'induction phase' of CY-induced tolerance is characterized by both selective allodepletion and nonspecific T-cell killing. In the 'transition phase', the alloreactive and regulatory forces come into balance, and the central tolerance becomes operational. In the 'maintenance phase', which follows the application of PT/CY, the above responses may be controlled by other immunosuppressive drugs. Ultimately, the development of tolerance and the establishment of mechanisms that maintain this process should allow the withdrawal of all immunosuppressants. 65, 66 More recently, Ross et al. 67 confirmed that although non-host alloantigen reactive donor T cells undergo some division early post transplant in the lymphopenic setting, CY can be administered on days 3-4 to spare these cells, while concomitantly depleting a sufficient level of anti-host alloreactive T cells to ameliorate GVHD.
PHARMACOLOGICAL AGENTS ATG A number of mechanisms are involved in the action of ATG. 11, 68, 69 (1) ATG causes TCD in blood and peripheral lymphoid tissues through complement-dependent lysis, T-cell activation and apoptosis; (2) ATG modulates key cell surface molecules, including integrin a4b7, VLA-4, CXCR4, CCR5 and CCR7, which mediate leukocyte/endothelium interactions; (3) ATG induces apoptosis in B-cell lineages and myeloma cell lines; (4) ATG inhibits the maturation of immature monocyte-derived DCs, which have a phenotype comparable to tolerogenic DCs; and (5) 75 but it also induces T-cell anergy and inhibits helper T-cell differentiation. 76 In addition to the strategies mentioned above, other methods have been investigated, including the induction of alloantigenspecific anergy ex vivo 77 and Treg-mediated, feto-maternal, microchimerism-induced immunological tolerance. [78] [79] [80] Using a mouse model, Fitzhugh et al. 81 found that when either sirolimus or PT/CY was given alone to C57BL/6 recipients, cells derived from the BALB/c donors were not detected. However, when sirolimus was administered for 15 or 31 days, starting 1 day before or up to 6 days after transplant with PT/CY, all mice maintained mixed chimerism. In contrast, conventional therapy that employed CsA with or without PT/CY did not result in stable mixed chimerism. Finally, mice with stable mixed chimerism after sirolimus displayed decreased reactivity to donor Ags, both in vitro and in vivo. These results suggest that sirolimus treatment in combination with PT/ CY may be a novel strategy for crossing HLA barriers. The numbers showed in these two columns represent the corresponding mechanisms or strategies, which are described in Table 1 . Indicates the underlying disease of this study included severe aplastic anemia.
81
d Indicates the underlying disease of this study included hematological malignancies and non-malignant disease.
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COMPARISON OF THE UNDERLYING MECHANISMS AND CLINICAL OUTCOMES OF DIFFERENT HAPLOIDENTICAL TRANSPLANTATION PROTOCOLS
Many haploidentical transplant protocols, such as T cell-replete transplantation and TCD transplantation, have been successfully established with promising clinical outcomes. 4, 43, 66, [82] [83] [84] [85] [86] The mechanisms underlying the crossing of HLA barriers and the transplant outcomes of different transplant protocols are summarized in Tables 1 and 2 , respectively. Each protocol may involve at least two mechanisms relevant to overcoming the HLA barriers and combining different strategies (Tables 1 and 2 , and Figure 1 ). 4, 6, 17, 66, [87] [88] [89] [90] [91] [92] The Perugia group established a haploidentical protocol that included TCD and a graft that contained a mega-dose of highly purified CD34 þ cells (average X10 Â 10 6 /kg body weight), which was administered following a myeloablative conditioning regimen. This protocol ensured a high engraftment rate, despite the HLA barrier, without triggering GVHD. 5, 16 However, despite the advantage of no GVHD development from this approach, a disadvantage of the CD34-selected haplotype transplant is a very slow immune recovery because of the small number of T cells that were infused in the graft. In addition, the application of ATG in this protocol can result in high rates of opportunistic infections, such as viral and fungal infections, which may cause non-relapse-related mortality. 5, 16 To accelerate immune recovery, the Perugia group 9 demonstrated for the first time that the adoptive transfer of Tregs could promote lymphoid reconstitution and improve immunity to opportunistic pathogens without weakening the GVL effect in TCD haploidentical settings. This finding suggests that adoptive transfer of gene-modified T cells 93 and/or pathogen-specific T cells 94 may be needed to improve clinical outcomes. In a phase II study, researchers from Germany found that haploidentical transplant with negative CD3/CD19 depletion and reduced intensity conditioning led to a successful transplantation in an older, heavily pretreated patient population. The estimated 2-year EFS was 25% in the study. The incidence of grade II-IV acute GVHD and chronic GVHD was 46% and 18%, respectively. 17 However, all of these methods are costly and cumbersome, require high expertise and cannot be widely implemented in most transplant centers.
Over the last 10 years, renewed interest has emerged in unmanipulated haploidentical transplantation. We have recently established an unmanipulated haploidentical blood and marrow transplantation (HBMT) protocol, and we have reported 756 patients who have undergone unmanipulated HBMT. 92 We found that the probabilities of OS and leukemia-free survival at 3 years were 67% and 63%, respectively. Our results suggest that G-CSF and the pharmacological agent, ATG, are the two strategies that effectively control the alloreactivity resulting from HLA mismatching. Although a large number of T cells in the allograft presumably promotes immune recovery, 95 the incidence of acute and chronic GVHD was higher in patients receiving HBMT compared with those receiving TCD haploidentical transplantation. 16, 17 These data suggest that the risk stratification-directed prophylaxis of GVHD (http://Clinical Trials.gov identifier NCT 01607580, 'Efficacy Study of Low-dose Glucocorticoid Prophylaxis for Acute Graft-versus-host Disease') should be explored as a method to decrease the incidence of acute GVHD following unmanipulated HBMT. More recently, Di Bartolomeo et al. 4 used a modified protocol (Italian protocol) that was developed by our group, 96, 97 and they achieved promising results in terms of the engraftment rate (93 ± 0.1% and 75 ± 0.2% for neutrophil and platelet, respectively), incidence of GVHD (24±0.2% and 17±0.3% for acute and chronic GVHD, respectively) and survival (45±6% for the 3-year probability of OS). These encouraging outcomes observed by Di Bartolomeo et al. 4 and ourselves 1, 92 suggest that G-CSF and pharmacological agent therapy may offset GVHD risk from multiple HLA disparities in both Caucasian and Chinese individuals.
A Baltimore group confirmed the feasibility of using high-dose PT/CY to overcome the HLA barrier. Luznik et al. 65 demonstrated that in 68 patients who underwent nonmyeloablative HLAhaploidentical BMT with PT/CY, the actuarial OS and EFS at 2 years after transplantation were 36% and 26%, respectively. The low number of T cells in allografts and disease status pretransplant were found to be possible contributors to the high cumulative incidence of relapse (51% at 1 year). 65 Therefore, methods to decrease relapse after haploidentical transplantation using PT/CY should be investigated. More recently, Raiola et al. 66 demonstrated that the actuarial OS and disease-free survival at 18 months post transplantation for patients who had undergone haploidentical BMT with myeloablative conditioning followed by PT/CY to induce tolerance were 62% and 51%, respectively. Based on the immune tolerance known to be induced by rapamycin and ATG, Ciceri et al. 98 established a calcineurin inhibitor-free GVHD prophylaxis to include rapamycin, mycophenolate mofetil and ATG (Fresenius). This prophylaxis was designed to promote rapid, post transplant immune recovery with preferential accumulation of Tregs (CD4 þ CD25 þ CD127 À Foxp3 þ ). Long-term follow-up is needed before definitive conclusions on the efficacy of this protocol can be drawn.
FUTURE PERSPECTIVES
Haploidentical SCT is an alternative therapeutic option for treating hematological diseases, which enables broad clinical use of allogeneic transplantation. 1, 3, 4, 66, 99 However, currently, there is no well-recognized standard haploidentical transplant protocol because each is based on the combination of different strategies with unique advantages and disadvantages (Tables 1 and 2 ; Figure 1) . 3, 8, 12, 24, 64 Therefore, investigating novel combinations of strategies that can be used to overcome HLA barriers is a necessary future research direction to establish improved haploidentical protocols. The best combination may rely on a variety of factors including disease subgroup, disease status pretransplantation and the goal of transplantation. For example, when treating patients with refractory/relapsed leukemia, the key goal is to enhance GVL effects. Therefore, unmanipulated haploidentical transplant settings are preferred because high T cells in allografts may contribute to GVL, although GVHD may be high. For pediatric patients with standard-risk leukemia, the GVL effects and health-related quality of life should be given equal attention. In these cases, TCD haploidentical transplantation is preferred. In summary, the ultimate goal is to establish a novel clinical haploidentical protocol that may be based on novel mechanisms of crossing HLA barriers and pre-clinical models. 13, 48 The novel protocol can be applied to all patients and will cause little or no GVHD or GR, provide rapid immune reconstitution, enhance the anti-leukemia and anti-pathogen immune responses and provide superior transplant outcomes. In this regard, the mechanisms of crossing HLA barriers that most likely to be explored in the future include anti-third-party Tcms, 13, 48 myeloidderived suppressor cell 20, 57 and regulatory B cells. 18, 100 These mechanisms may have the greatest effect on the establishment of novel haploidentical transplant protocols.
